Navigation Links
DURECT Corporation Announces First Quarter 2012 Financial Results and Update of Programs
Date:5/3/2012

as an issued European patent providing coverage to at least 2023."

Update of Programs:

  • REMOXY (oxycodone) Extended-Release Capsules CIIPfizer has efforts underway to resolve the issues raised in the REMOXY Complete Response Letter and stated in its earnings call on January 31, 2012 that it expects to conduct two bioavailability studies in the second quarter of 2012 and then meet with the FDA in the third quarter to discuss next steps.  The issues raised in the Complete Response Letter relate primarily to manufacturing.
  • REMOXY, an investigational drug, is a unique long acting oral formulation of oxycodone intended to treat moderate to severe pain. Based on DURECT's ORADUR technology, which is covered by issued patents and pending patent applications owned by us, REMOXY is designed to discourage common methods of tampering associated with prescription opioid analgesic misuse and abuse.

  • POSIDUR (SABER®-Bupivacaine) Post-Operative Pain Relief Depot. Preparation of our briefing package is well underway for our scheduled pre-NDA meeting with the FDA in the summer of 2012, with a potential NDA submission later in the year, depending on FDA feedback. 
  • POSIDUR is our post-operative pain relief depot that utilizes our patented SABER technology to deliver bupivacaine to provide up to three days of pain relief after surgery.  We currently hold worldwide commercialization rights to POSIDUR following the notice given in the first quarter of 2012 by Hospira and Nycomed to terminate their collaborations related to the program.

  • Transdermal Development Candidates.
    DURECT has two transdermal products that are in mid- to late-stage development with features that may be superior to currently available patches.  TRANSDUR-Sufentanil is our proprietary transdermal patch intended to del
    '/>"/>

  • SOURCE DURECT Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. DURECT Announces Issuance of U.S. Patents Covering ORADUR® Technology
    2. DURECT Corporation Invites You to Join Its Fourth Quarter 2011 Earnings Conference Call
    3. DURECT to Participate in Upcoming Healthcare Conferences
    4. DURECT Announces Top-line Data from BESST (POSIDUR® U.S. Pivotal Phase III Trial)
    5. DURECT Corporation Invites You to Join its Third Quarter 2011 Earnings Conference Call
    6. DURECT Completes Enrollment in Pivotal U.S. Phase III Trial for POSIDUR® (BESST)
    7. DURECT Corporation to Participate in Upcoming Healthcare Conferences
    8. DURECT Corporation Announces Second Quarter 2011 Financial Results and Update of Programs
    9. DURECT Corporation Invites You to Join its Second Quarter 2011 Earnings Conference Call
    10. DURECT to Present at the Jefferies Healthcare Conference
    11. DURECT Announces Resignation of Chief Medical Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
    (Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
    (Date:12/22/2014)... Calif. , Dec. 22, 2014 Apnea ... expanded corporate offices in Aliso Viejo ... that due to the tremendous growth and worldwide expansion, ... Sales of patented SnoreRx, the anti snore cure have ... He said, "We are now in 23 countries ...
    Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
    ... LEUVEN, Belgium, June 25 , ... for the,Non-Surgical Treatment of Eye Disease With No Reported Safety ... THR), a biotechnology company,focused on the discovery and development of ... that its lead product,microplasmin, which is in Phase III trials ...
    ... personalized chemotherapy can improve cure rate and avoid the ... , , MEMPHIS, Tenn., June 24 ... treated using a carefully personalized chemotherapy regimen without cranial ... found. Such radiation of the brain was once a ...
    Cached Medicine Technology:ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 2ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule 3Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation 2Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation 3Acute Lymphoblastic Leukemia, the Most Common Childhood Cancer, Is Curable Without Preventive Cranial Radiation 4
    (Date:12/26/2014)... (PRWEB) December 26, 2014 India Network ... insurance in the USA, announced today a new version ... members in choosing the right plan for their visiting ... complexity out of the selection process when choosing an ... age group with only a few clicks. Many elderly ...
    (Date:12/26/2014)... (PRWEB) December 26, 2014 Parker ... for the best in heating, cooling and plumbing ... 24 hour emergency services in 2014 with regard ... know that Arizona is known for its incredibly ... that understands the intricacies and details of a ...
    (Date:12/25/2014)... The click strand woven bamboo flooring ... the business announces a click strand woven bamboo ... 2015. , Click strand woven bamboo flooring replicates ... well-known brand in the bamboo industry. It promises ... bamboo flooring supplier. , “We are happy to ...
    (Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
    (Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
    Breaking Medicine News(10 mins):Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
    ... advertising helps reduce adult smoking, according to a study by ... Health Research and Policy -- but some ads may be ... to a variety of anti-smoking messages on television. However, no ... various sponsors, impact adult smoking behaviors, or on how the ...
    ... Anaesthetists have identified a major shortfall in funding for emergency ... to establish a more accurate picture of outcomes and costs. ... suggest a shortfall of 300 million per year for emergency ... care. The study also found that emergency laparotomy, ...
    ... , This press release is available in ... conducted with thousands of local teenagers by University of ... or ecstasy (MDMA) at fifteen or sixteen years of ... symptoms the following year. "Our findings are consistent with ...
    ... By Kathleen Doheny HealthDay Reporter , WEDNESDAY, April ... the American Heart Association says no convincing evidence exists linking ... there strong evidence that treating gum disease can reduce your ... For more than 100 years, it was said that gum, ...
    ... Cancer Agency and University of British Columbia have identified ... the disease is diagnosed and form the basis of ... 10 completely new categories based on the genetic fingerprint ... much-needed insight into breast cancer biology, allowing doctors to ...
    ... and quality-of-life issues should be considered essential elements of ... point of breast cancer diagnosis. However, for women suffering ... other medically underserved areas around the world, this fundamental ... To address these issues, many of the world,s ...
    Cached Medicine News:Health News:Anti-tobacco TV ads help adults stop smoking, study finds 2Health News:Study reveals major funding shortfall and high death rates for emergency laparotomy 2Health News:Study reveals major funding shortfall and high death rates for emergency laparotomy 3Health News:Speed and ecstasy associated with depression in teenagers 2Health News:No Proof That Gum Disease Causes Heart Disease, Experts Say 2Health News:No Proof That Gum Disease Causes Heart Disease, Experts Say 3Health News:Scientists rewrite rulebook on breast cancer in landmark global study 2Health News:Scientists rewrite rulebook on breast cancer in landmark global study 3Health News:International breast health global summit will focus on supportive care and quality of life 2Health News:International breast health global summit will focus on supportive care and quality of life 3
    Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Straight....
    3 mm forked angled blades. Blade spread 7 mm. Flat serrated handle with polished finish. Overall length: 4.8 inches....
    Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
    Flat 7 mm wide hook. Flat serrated handle with polished finish. Overall length: 5.1 inches....
    Medicine Products: